KR20160132470A - 피페리딘-다이온 유도체 - Google Patents
피페리딘-다이온 유도체 Download PDFInfo
- Publication number
- KR20160132470A KR20160132470A KR1020167028584A KR20167028584A KR20160132470A KR 20160132470 A KR20160132470 A KR 20160132470A KR 1020167028584 A KR1020167028584 A KR 1020167028584A KR 20167028584 A KR20167028584 A KR 20167028584A KR 20160132470 A KR20160132470 A KR 20160132470A
- Authority
- KR
- South Korea
- Prior art keywords
- thienyl
- piperidine
- dione
- pyridyl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *C(CC(C1[Al]c2c(*)ccc(*)c2)=O)(*C1=O)C1=C(*)C(*)=C(*)**1 Chemical compound *C(CC(C1[Al]c2c(*)ccc(*)c2)=O)(*C1=O)C1=C(*)C(*)=C(*)**1 0.000 description 7
- CMLJOQIDKSBZPC-UHFFFAOYSA-N O=C(c(cc1)ccc1F)c1nc(C(CC(C2Sc3ccccc3Cl)=O)(c3c[s]cc3)NC2=O)ccc1 Chemical compound O=C(c(cc1)ccc1F)c1nc(C(CC(C2Sc3ccccc3Cl)=O)(c3c[s]cc3)NC2=O)ccc1 CMLJOQIDKSBZPC-UHFFFAOYSA-N 0.000 description 2
- PWOBDMNCYMQTCE-UHFFFAOYSA-N Sc(cccc1)c1Cl Chemical compound Sc(cccc1)c1Cl PWOBDMNCYMQTCE-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- CWTXTOGCCMEZEP-UHFFFAOYSA-N CC(C)(C)OC(NS)=O Chemical compound CC(C)(C)OC(NS)=O CWTXTOGCCMEZEP-UHFFFAOYSA-N 0.000 description 1
- BEULLKPQAJNAKI-UHFFFAOYSA-O CC(C)(C)S(N)[OH2+] Chemical compound CC(C)(C)S(N)[OH2+] BEULLKPQAJNAKI-UHFFFAOYSA-O 0.000 description 1
- WCWWJVWZFFPHPC-UHFFFAOYSA-N CNS(N1CCC1)(=O)=O Chemical compound CNS(N1CCC1)(=O)=O WCWWJVWZFFPHPC-UHFFFAOYSA-N 0.000 description 1
- AIQCCROBLVQQFA-UHFFFAOYSA-N Cc1ccc(C(CC(C2)=O)(c3c[s]cc3)N/C2=[O]/C)cc1 Chemical compound Cc1ccc(C(CC(C2)=O)(c3c[s]cc3)N/C2=[O]/C)cc1 AIQCCROBLVQQFA-UHFFFAOYSA-N 0.000 description 1
- RJUWELYLXBAVKY-KUXRGDIISA-N N=C(/C=C\CCCBr)Br Chemical compound N=C(/C=C\CCCBr)Br RJUWELYLXBAVKY-KUXRGDIISA-N 0.000 description 1
- UDAMDYKQPRENOU-UHFFFAOYSA-N O=C(CC(c(cc1)ccc1N1CCOCC1)(c1cccc(Br)n1)N1)CC1=O Chemical compound O=C(CC(c(cc1)ccc1N1CCOCC1)(c1cccc(Br)n1)N1)CC1=O UDAMDYKQPRENOU-UHFFFAOYSA-N 0.000 description 1
- WZGFUBMTAAFBMO-UHFFFAOYSA-N O=C(CC(c(cc1)ccc1N1CCOCC1)(c1cccc(Br)n1)NC1=O)C1Sc1ccccc1Cl Chemical compound O=C(CC(c(cc1)ccc1N1CCOCC1)(c1cccc(Br)n1)NC1=O)C1Sc1ccccc1Cl WZGFUBMTAAFBMO-UHFFFAOYSA-N 0.000 description 1
- BMJWPDWAOKBEIJ-UHFFFAOYSA-N O=C(CC(c1c[s]cc1)(c(cc1)ccc1C1=CCCCC1)NC1=O)C1Sc(cccc1)c1Cl Chemical compound O=C(CC(c1c[s]cc1)(c(cc1)ccc1C1=CCCCC1)NC1=O)C1Sc(cccc1)c1Cl BMJWPDWAOKBEIJ-UHFFFAOYSA-N 0.000 description 1
- HABILWTZSVCETE-UHFFFAOYSA-N O=C(CC(c1c[s]cc1)(c1cccc(Br)n1)NC1=O)C1Sc1ccccc1Cl Chemical compound O=C(CC(c1c[s]cc1)(c1cccc(Br)n1)NC1=O)C1Sc1ccccc1Cl HABILWTZSVCETE-UHFFFAOYSA-N 0.000 description 1
- GKJSSCXBKYYEHN-UHFFFAOYSA-N O=C(c(cc1)ccc1N1CCOCC1)c1cccc(Br)n1 Chemical compound O=C(c(cc1)ccc1N1CCOCC1)c1cccc(Br)n1 GKJSSCXBKYYEHN-UHFFFAOYSA-N 0.000 description 1
- FOAQOAXQMISINY-UHFFFAOYSA-N O=Cc(cc1)ccc1N1CCOCC1 Chemical compound O=Cc(cc1)ccc1N1CCOCC1 FOAQOAXQMISINY-UHFFFAOYSA-N 0.000 description 1
- PPPGGUWGGOHTKS-UHFFFAOYSA-N Oc(cc1)cc(S)c1Cl Chemical compound Oc(cc1)cc(S)c1Cl PPPGGUWGGOHTKS-UHFFFAOYSA-N 0.000 description 1
- GEXUPNMZFMINSX-UHFFFAOYSA-N Oc(cc1SC(C(CC(c2c[s]cc2)(c(cc2)ccc2N2CCCCC2)N2)=O)C2=O)ccc1Cl Chemical compound Oc(cc1SC(C(CC(c2c[s]cc2)(c(cc2)ccc2N2CCCCC2)N2)=O)C2=O)ccc1Cl GEXUPNMZFMINSX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014073509 | 2014-03-17 | ||
| CNPCT/CN2014/073509 | 2014-03-17 | ||
| CNPCT/CN2014/083613 | 2014-08-04 | ||
| CN2014083613 | 2014-08-04 | ||
| PCT/EP2015/055495 WO2015140133A1 (en) | 2014-03-17 | 2015-03-17 | Piperidine-dione derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160132470A true KR20160132470A (ko) | 2016-11-18 |
Family
ID=52697396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167028584A Withdrawn KR20160132470A (ko) | 2014-03-17 | 2015-03-17 | 피페리딘-다이온 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170001990A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3119760A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017512783A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160132470A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106573906A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016015365A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2935071A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA39749A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016011992A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016137674A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015140133A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017055396A1 (en) * | 2015-09-30 | 2017-04-06 | Selvita S.A. | Pyrazolidine derivatives and related compounds |
| US10954228B2 (en) | 2016-06-29 | 2021-03-23 | The Trustees Of The University Of Pennsylvania | 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof |
| GB201707852D0 (en) * | 2017-05-16 | 2017-06-28 | Arctic Pharma As | Compounds |
| GB201707846D0 (en) * | 2017-05-16 | 2017-06-28 | Spermatech As | Use |
| GB201707856D0 (en) * | 2017-05-16 | 2017-06-28 | Arctic Pharma As | Compounds |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN109369631B (zh) * | 2018-12-11 | 2020-06-30 | 上海皓元生物医药科技有限公司 | 一种用于合成乳酸脱氢酶a抑制剂的关键中间体的合成方法 |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| CN112142711B (zh) * | 2019-06-28 | 2022-03-29 | 中国科学院上海药物研究所 | 取代噻吩类化合物、其制备方法及其用途 |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN110776452B (zh) * | 2019-11-25 | 2023-02-14 | 陕西师范大学 | 一锅法制备吡咯烷衍生物和哌啶衍生物的方法 |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| CN122234044A (zh) * | 2026-05-14 | 2026-06-19 | 四川大学华西医院 | 靶向乳酸脱氢酶的protac化合物及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840751A (en) * | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
-
2015
- 2015-03-17 MX MX2016011992A patent/MX2016011992A/es unknown
- 2015-03-17 RU RU2016137674A patent/RU2016137674A/ru not_active Application Discontinuation
- 2015-03-17 EP EP15711118.8A patent/EP3119760A1/en not_active Withdrawn
- 2015-03-17 CA CA2935071A patent/CA2935071A1/en not_active Abandoned
- 2015-03-17 MA MA039749A patent/MA39749A/fr unknown
- 2015-03-17 BR BR112016015365A patent/BR112016015365A8/pt not_active Application Discontinuation
- 2015-03-17 KR KR1020167028584A patent/KR20160132470A/ko not_active Withdrawn
- 2015-03-17 WO PCT/EP2015/055495 patent/WO2015140133A1/en not_active Ceased
- 2015-03-17 CN CN201580025598.2A patent/CN106573906A/zh active Pending
- 2015-03-17 JP JP2016558080A patent/JP2017512783A/ja active Pending
-
2016
- 2016-09-15 US US15/266,222 patent/US20170001990A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106573906A (zh) | 2017-04-19 |
| MA39749A (fr) | 2017-01-25 |
| BR112016015365A8 (pt) | 2020-06-02 |
| BR112016015365A2 (cg-RX-API-DMAC7.html) | 2017-08-08 |
| EP3119760A1 (en) | 2017-01-25 |
| MX2016011992A (es) | 2016-12-05 |
| US20170001990A1 (en) | 2017-01-05 |
| JP2017512783A (ja) | 2017-05-25 |
| RU2016137674A3 (cg-RX-API-DMAC7.html) | 2018-10-10 |
| CA2935071A1 (en) | 2015-09-24 |
| RU2016137674A (ru) | 2018-04-18 |
| WO2015140133A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015140133A1 (en) | Piperidine-dione derivatives | |
| JP5789259B2 (ja) | 含窒素芳香族複素環誘導体 | |
| JP4667537B2 (ja) | アシルチオウレア化合物又はその塩、及びその用途 | |
| EP3672948B1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| KR102383739B1 (ko) | Wnt 경로 조절제 | |
| CN106061974B (zh) | 作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 | |
| KR20150020228A (ko) | 아미노퀴나졸린 및 피리도피리미딘 유도체 | |
| JP2016527296A (ja) | Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン | |
| WO2002032872A1 (fr) | Composes a noyau aromatique azote | |
| KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
| KR20160101899A (ko) | 브로모도메인 억제제 | |
| KR20150065191A (ko) | 헤테로방향족 화합물 및 도파민 d1 리간드로서 이의 용도 | |
| CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
| WO2023072096A1 (zh) | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 | |
| US11548900B2 (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| US12552785B2 (en) | Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof | |
| CN121226261A (zh) | 作为wrn抑制剂的含芳香环化合物及其应用 | |
| JP2021530455A (ja) | 三環式化合物 | |
| HK40092606A (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| RU2804638C2 (ru) | Пиридинаминпиридоны и пиримидинаминпиридоны | |
| HK1233261A1 (en) | Piperidine-dione derivatives | |
| HK40030344B (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| HK40030344A (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161014 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |